ContraVir Pharmaceuticals Becomes Hepion Pharmaceuticals

ContraVir Pharmaceuticals, Inc. has approved the change of the Company’s name and stock symbol to Hepion Pharmaceuticals, Inc. and "HEPA," respectively.
 
"We derived the name ‘Hepion’ by combining the ancient Greek word for liver, ‘hepar,’ with ‘Epione,’ the goddess of soothing, or healing," commented Dr. Robert Foster, the Company’s CEO. "Changing the Company’s name to Hepion Pharmaceuticals is a reflection of the significant potential our lead candidate, CRV431, has to treat inflammation, fibrosis, and hepatocellular carcinoma associated with liver disease, in addition to its potential as an antiviral."
 
Hepion is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. 

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com